The First Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
The First Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Int J Surg. 2018 Aug;56:242-249. doi: 10.1016/j.ijsu.2018.06.033. Epub 2018 Jun 27.
To explore the relationships between the expression level of different galectins and its prognostic value for patients with gastric cancer.
The PubMed, EMbase, the Cochrane Library and Web of Science databases were systematically searched. All the eligible studies were included according to the inclusion and exclusion criteria. All the relevant data was extracted by two independent researchers. The quality assessment was conducted according to the evaluation of the quality of prognosis study which published by Harden in 2006. The STATA 12.0 software was used to perform a meta-analysis.
All of 8 retrospective case-controlled studies involving 2093 patients with gastric cancer were included in this study. The results of meta-analysis presented that the elevated galectin-1 which is related to the poor overall survival (HR = 1.85, 95% CI: 1.33-2.58; P < 0.001) may predicted a larger tumor size (OR = 2.20, 95% CI: 1.35-3.35; P = 0.001) and was positively associated with the higher expression of VEGF (OR = 1.44, 95% CI: 1.14-1.82; P = 0.002). Moreover, the decreased galectin-3 (HR = 0.49, 95% CI: 0.36-0.67; P < 0.001), galectin-8 (HR = 0.49, 95% CI: 0.36-0.67; P < 0.001) and galectin-9 (HR = 0.78, 95% CI: 0.66-0.92; P = 0.003) were also significantly associated with poorer prognosis. Our meta-analysis also showed that lower expression of galectin-3 was also related to lymphatic vessel invasion (OR = 0.48, 95% CI: 0.26-0.89; P = 0.018), worse TNM stages (OR = 0.47, 95% CI: 0.32-0.40; P < 0.001), deeper invasive depth (OR = 0.33, 95% CI: 0.21-0.51; P < 0.001) and poorer differentiation grade (OR = 0.10, 95% CI: 0.04-0.25; P < 0.001).
High expression of galectin-1 or low expression of galectin-3, -8 and -9 were significantly related to a poorer prognosis for patients with gastric cancer. The expression level of galectins was associated with clinical characteristics and were potential independent prognostic predictor for GC patients.
探讨不同半乳糖凝集素的表达水平与胃癌患者预后的关系。
系统检索 PubMed、EMbase、Cochrane 图书馆和 Web of Science 数据库。根据纳入和排除标准,纳入所有符合条件的研究。两名独立研究人员提取所有相关数据。根据 Harden 于 2006 年发表的预后研究质量评估标准对质量进行评估。使用 STATA 12.0 软件进行荟萃分析。
共纳入 8 项回顾性病例对照研究,共计 2093 例胃癌患者。荟萃分析结果表明,与总生存期较差相关的高表达半乳糖凝集素-1(HR=1.85,95%CI:1.33-2.58;P<0.001)可能预示着肿瘤体积更大(OR=2.20,95%CI:1.35-3.35;P=0.001),并且与 VEGF 的高表达呈正相关(OR=1.44,95%CI:1.14-1.82;P=0.002)。此外,半乳糖凝集素-3(HR=0.49,95%CI:0.36-0.67;P<0.001)、半乳糖凝集素-8(HR=0.49,95%CI:0.36-0.67;P<0.001)和半乳糖凝集素-9(HR=0.78,95%CI:0.66-0.92;P=0.003)的表达降低也与预后不良显著相关。我们的荟萃分析还表明,半乳糖凝集素-3 的低表达也与淋巴管侵犯(OR=0.48,95%CI:0.26-0.89;P=0.018)、更差的 TNM 分期(OR=0.47,95%CI:0.32-0.40;P<0.001)、更深的侵袭深度(OR=0.33,95%CI:0.21-0.51;P<0.001)和更差的分化程度(OR=0.10,95%CI:0.04-0.25;P<0.001)相关。
半乳糖凝集素-1 高表达或半乳糖凝集素-3、-8 和-9 低表达与胃癌患者预后不良显著相关。半乳糖凝集素的表达水平与临床特征相关,是 GC 患者潜在的独立预后预测因子。